Evidence map›Paper›PMID 25256711›Full record

ArticleMolecular cancer research : MCR2014

A functional screen identifies miRs that induce radioresistance in glioblastomas.

Patryk Moskwa, Pascal O Zinn, Young Eun Choi, Sachet A Shukla, Wojciech Fendler, Clark C Chen, Jun Lu, Todd R Golub, Anita Hjelmeland, Dipanjan Chowdhury

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. There and Back Again: The Middle Earth of DNA Repair.Molecular cancer research : MCR · 2016
    Article
  18. Article
  19. Review
  20. Novel and emerging targeted-based cancer therapy agents and methods.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Patryk MoskwaDepartment of Radiation Oncology, Division of Genomic Stability and DNA Repair, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Internal Medicine A, Medical University of Greifswald, Ferdinand-Sauerbruchstrasse, Greifswald, Germany.
Pascal O ZinnDepartment of Neurosurgery, Baylor College of Medicine and M Anderson Cancer Center, Houston, Texas.
Young Eun ChoiDepartment of Radiation Oncology, Division of Genomic Stability and DNA Repair, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Sachet A ShuklaDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Wojciech FendlerDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland.
Clark C ChenCenter for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, Division of Neurosurgery, University of California San Diego, San Diego, California.
Jun LuYale Stem Cell Center and Department of Genetics, Yale University, New Haven, Connecticut.
Todd R GolubBroad Institute of MIT and Harvard, Cambridge, Massachusetts. Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Howard Hughes Medical Institute, Chevy Chase, Maryland.
Anita HjelmelandDepartment of Cell, Developmental, and Integrative Biology University of Alabama at Birmingham, Birmingham, Alabama.
Dipanjan ChowdhuryDepartment of Radiation Oncology, Division of Genomic Stability and DNA Repair, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. dipanjan_chowdhury@dfci.harvard.edu.
Howard Hughes Medical Institute · US

Funding

Molecular mechanism and relevance of microRNAs in DSB repair pathway choiceR01CA142698 · NCI · DANA-FARBER CANCER INST · PI CHOWDHURY, DIPANJAN · 2010 to 2019
$3.8M
Serum microRNA as biomarker for radiation injury to lung and hematopoietic cellsR01AI101897 · NIAID · DANA-FARBER CANCER INST · PI CHOWDHURY, DIPANJAN · 2012 to 2016
$2.1M
A20 Promotes Glioma Stem Cell Mediated TumorigenesisR01CA151522 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HJELMELAND, ANITA BORTON · 2010 to 2014
$1.2M
NCI NIH HHS R01 CA142698NCI NIH HHS R01CA142698NCI NIH HHS R01 CA151522NCI NIH HHS R01CA151522NIAID NIH HHS R01 AI101897NIAID NIH HHS R01 AI101897-01
6 · The paper itself

Abstract

unlabelledThe efficacy of radiotherapy in many tumor types is limited by normal tissue toxicity and by intrinsic or acquired radioresistance. Therefore, it is essential to understand the molecular network responsible for regulating radiosensitivity/resistance. Here, an unbiased functional screen identified four microRNAs (miR1, miR125a, miR150, and miR425) that induce radioresistance. Considering the clinical importance of radiotherapy for patients with glioblastoma, the impact of these miRNAs on glioblastoma radioresistance was investigated. Overexpression of miR1, miR125a, miR150, and/or miR425 in glioblastoma promotes radioresistance through upregulation of the cell-cycle checkpoint response. Conversely, antagonizing with antagomiRs sensitizes glioblastoma cells to irradiation, suggesting their potential as targets for inhibiting therapeutic resistance. Analysis of glioblastoma datasets from The Cancer Genome Atlas (TCGA) revealed that these miRNAs are expressed in glioblastoma patient specimens and correlate with TGFβ signaling. Finally, it is demonstrated that expression of miR1 and miR125a can be induced by TGFβ and antagonized by a TGFβ receptor inhibitor. Together, these results identify and characterize a new role for miR425, miR1, miR125, and miR150 in promoting radioresistance in glioblastomas and provide insight into the therapeutic application of TGFβ inhibitors in radiotherapy. IMPLICATIONS: Systematic identification of miRs that cause radioresistance in gliomas is important for uncovering predictive markers for radiotherapy or targets for overcoming radioresistance.

Indexed as

Radiation ToleranceCell Cycle CheckpointsCell Line, TumorGene Expression Regulation, NeoplasticGlioblastomaHumansMicroRNAsSignal TransductionTransforming Growth Factor betaMicroRNAsMIR150, humanMIRN125 microRNA, humanMIRN1 microRNA, humanMIRN425 microRNA, humanTransforming Growth Factor beta

Identifiers

PMID25256711
PMCPMC4386891
OpenAlexW1971862810

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.